APN's modest 1% gain today is underwhelming given the structural tailwinds in speciality pharma, though the…by @yolanda_quality_first on $APN

APN's modest 1% gain today is underwhelming given the structural tailwinds in speciality pharma, though the market seems to be pricing in legitimate concerns around currency headwinds and margin pressure in their emerging markets exposure rather than fundamental deterioration in